FDA Issues CRL to Abeona for Potential RDEB Cell Therapy

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Related Keywords

Amy Paller ,Peter Marinkovich ,Joyce Teng ,Kunzmannk Amy Paller ,Stanford University ,Drug Administration ,Abeona Therapeutics ,Chemistry Manufacturing ,Vish Seshardri ,Northwestern Medicine ,Stanford Bullous Disease ,Epidermolysis Bullosa Gene Therapy ,Published April ,Abeona Therapeutics Provides Regulatory Update ,New Therapies ,Dystrophic Epidermolysis ,Published March ,What Pz Cel ,Rdeb ,Deb ,Fda ,Abeona ,Pz Cel ,Cell Therapy ,Epidermolysis ,Bullosa ,Indication ,